Panzyga

What Panzyga does

Panzyga® (Immune Globulin Intravenous [Human] – IFAS) is a 10% liquid preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma, manufactured by Octapharma AG and marketed in the United States by its wholly-owned subsidiary Octapharma USA, Inc., headquartered in Paramus, New Jersey. The product is solvent/detergent-treated and sterile, stabilized with glycine, and contains no preservatives or sucrose. It is manufactured using caprylic acid fractionation combined with chromatography and is available in five vial sizes ranging from 2.5 g/25 mL to 30 g/300 mL, with a 36-month shelf life at 2–8°C.

The business is a single-asset, prescription pharmaceutical operation targeting three FDA-approved indications: primary immunodeficiency (PI) in patients aged 2 and older, chronic immune thrombocytopenia (cITP) in adults, and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. Panzyga holds two regulatory exclusivities: it is the only IVIg with two FDA-approved maintenance dosing options for adult CIDP (1 g/kg and 2 g/kg every 3 weeks), and the only IVIg with an FDA-approved infusion rate of up to 14 mg/kg/min for PI. Clinical data demonstrate an 92% INCAT response rate at the 2 g/kg CIDP dose, an 81% platelet response rate in cITP within 7 days, and 0.08 serious bacterial infections per PI patient per year.

Panzyga generates revenue through prescription pharmaceutical sales to U.S. healthcare providers and health systems, billed either through medical benefits or pharmacy benefits, with distribution to hospitals, infusion centers, and specialty pharmacies. The go-to-market is a field sales model executed by Octapharma USA representatives, with co-pay assistance of up to $12,500 per calendar year for eligible commercially insured patients (Medicare/Medicaid excluded). The target audience is exclusively U.S. healthcare professionals, supported by dedicated customer service, reimbursement, drug safety, and Medical Affairs contact lines. The product is not a standalone company, has no external funding, and operates as a U.S. brand within Octapharma AG's global plasma-derived therapeutics portfolio.

Name

Panzyga

Legal name

Octapharma USA, Inc.

Website

https://panzygausa.com

Company type

Private

Operating status

Operating

Short description

Panzyga® is an FDA-approved 10% liquid intravenous immunoglobulin (IVIg) product marketed by Octapharma USA in the U.S. for treating primary immunodeficiency, chronic immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy in adults, sold via field sales to healthcare providers.

Ownership category

akta.pro rank

Product category

Intravenous Immunoglobulin (IVIg) Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAIAHAA

Immunoglobulins (IVIG/SCIG)

Healthcare & Life Sciences/Pharmaceuticals/Plasma-Derived Therapies

SECONDARYHLAAAEAH

Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins)

Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

SECONDARYHLAIAHAE

Hyperimmune (Specific) Immunoglobulins (e.g., Anti-D, Tetanus, Rabies, Hep B)

Healthcare & Life Sciences/Pharmaceuticals/Plasma-Derived Therapies

Keywords

• Intravenous immunoglobulin therapy
• Plasma-derived therapeutics
• Biologic pharmaceutical products
• Immune globulin treatments
• Prescription biologic drugs

Headquarters

HQ city

Paramus

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Prescription Pharmaceutical Sales: Panzyga is an FDA-approved biologic/pharmaceutical product sold by prescription for treatment of CIDP, cITP, and PI. Revenue is generated through direct sales to healthcare providers and health systems, billed either through medical benefits or pharmacy benefits.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Panzyga® (Immune Globulin Intravenous [Human] – IFAS) is an FDA-approved 10% liquid preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma, manufactured by Octapharma USA, Inc. The product is solvent/detergent-treated, sterile, glycine-stabilized, and available in five vial sizes (2.5g, 5g, 10g, 20g, 30g) for intravenous infusion in adult CIDP and cITP patients and PI patients aged 2 years and older.

Product overview

Panzyga is a single FDA-approved biopharmaceutical product — Panzyga® (Immune Globulin Intravenous [Human] – IFAS) 10% Liquid Preparation — manufactured by Octapharma USA. It is a solvent/detergent-treated, sterile preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma. The product is indicated for three therapeutic uses: chronic inflammatory demyelinating polyneuropathy (CIDP), chronic immune thrombocytopenia (cITP), and primary immunodeficiency (PI). Panzyga® is available in five vial sizes (2.5g, 5g, 10g, 20g, and 30g) and offers different FDA-approved dosing and infusion rates depending on the indication (up to 14 mg/kg/min for PI, 12 mg/kg/min for CIDP, and 8 mg/kg/min for cITP). The product is stored for 36 months at 2°C to 8°C or up to 12 months at room temperature (≤25°C).

Differentiator

Problem solved

Functional benefit

Products and services

• Panzyga® (Immune Globulin Intravenous [Human] – IFAS) 10% Liquid Preparation Panzyga® is an FDA-approved solvent/detergent-treated, sterile 10% liquid preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma, for intravenous infusion in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in adults, chronic immune thrombocytopenia (cITP) in adults, and primary immunodeficiency (PI) in patients 2 years and older. Available in five vial sizes (2.5g/25mL, 5g/50mL, 10g/100mL, 20g/200mL, 30g/300mL) with FDA-approved infusion rates up to 14 mg/kg/min (PI), 12 mg/kg/min (CIDP), and 8 mg/kg/min (cITP). Administered by healthcare professionals in clinical settings and billed through medical or pharmacy benefits.

Quantifiable outcome

• 80% of CIDP patients achieved INCAT response at 1 g/kg dose; 92% at 2 g/kg dose after 6 months
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Octapharma USA, Inc.coreOthersOctapharma USA, Inc. is the manufacturer and marketer of Panzyga. The company is headquartered in Paramus, NJ and provides full product support including customer service (866-766-4860), reimbursement support (800-554-4440), drug safety (201-604-1137), and Medical Affairs (888-429-4535).

Scale indicators6 records

Recent moves5 records

Emerging players

• HyQvia: Takeda's facilitated SCIG (subcutaneous IG with hyaluronidase) for PI; a next-generation administration modality that competes with Panzyga's IVIG for PI patients, particularly those preferring home infusion.
• Hizentra: CSL Behring's 20% SCIG for PI and CIDP maintenance; a leading subcutaneous alternative that competes with Panzyga's IVIG for chronic-use patients seeking at-home administration.
• Bivigam / Asceniv: ADMA Biologics's IVIG products (Bivigam for PI; Asceniv for PI) marketed as a smaller, U.S.-based IVIG supplier; competes with Panzyga primarily in the primary immunodeficiency segment.

Others

• Octagam: Octapharma's other IVIG product (5% and 10%) sold in Europe and other markets; comparable technology (same parent) but a sister product rather than a direct U.S. competitor to Panzyga.

Direct peers

• Gammaplex: Bio Products Laboratory's 5% and 10% IVIG for PI and ITP; a direct IVIG class competitor with overlapping indications and similar hospital/specialty pharmacy distribution.
• Flebogamma DIF: Grifols's 5% and 10% IVIG for PI and ITP; one of the established IVIG alternatives competing with Panzyga in the U.S. specialty distribution channel.
• Gammagard Liquid: Takeda's 10% IVIG indicated for PI and multifocal motor neuropathy; competes with Panzyga in PI and the broader IVIG class with significant market share.
• Privigen: CSL Behring's 10% IVIG product for PI, CIDP, and ITP; the most widely used IVIG globally and Panzyga's most direct head-to-head competitor in the U.S. across overlapping indications.
• Gamunex-C: Grifols's 10% IVIG approved for PI, ITP, and CIDP, directly competing with Panzyga across the same three indications and the same neurology/hematology specialty channel.

Regional players

• Kedrion (human IG portfolio): Kedrion distributes IVIG and plasma products in select markets; comparable plasma-derived IG manufacturer but with limited U.S. commercial presence relative to Panzyga.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Panzyga